Trifluridine/Tipiracil + Oxaliplatin for Esophageal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well trifluridine/tipiracil and oxaliplatin work as the first line of treatment (induction) in treating patients with esophageal or gastroesophageal junction adenocarcinoma that can be removed by surgery (resectable). Drugs used in chemotherapy, such as trifluridine/tipiracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Who Is on the Research Team?
Christos Fountilas, MD
Principal Investigator
Roswell Park Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults with a specific type of cancer in the esophagus or where it meets the stomach, which can still be surgically removed. They should not have had previous treatments for this cancer and must be generally healthy with good organ function. Participants need to understand the study and agree to use effective birth control if they can have children.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Chemotherapy
Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles.
Chemoradiation and Surgery
Patients undergo standard of care chemoradiation therapy followed by surgery.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Oxaliplatin
- Trifluridine and Tipiracil Hydrochloride
Oxaliplatin is already approved in European Union, United States, Canada, Japan, Switzerland, China for the following indications:
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor
National Comprehensive Cancer Network
Collaborator